Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes

Area of Science:

• Immunology
• Molecular Biology

Background:

• Interleukin-10 (IL-10) confers protection against lethal endotoxemia.
• IL-10 inhibits inflammatory cytokine production, such as tumor necrosis factor-alpha (TNF-alpha).
• The mechanism by which IL-10 inhibits nuclear factor-kappaB (NF-kappaB) activation is not fully understood, but NF-kappaB activation requires degradation of its inhibitor, IkappaB-alpha.

Purpose of the Study:

• To investigate the effect of IL-10 on lipopolysaccharide (LPS)-induced TNF-alpha production in human monocytes.
• To determine if IL-10 influences NF-kappaB activation and IkappaB-alpha degradation in response to LPS.
• To test the hypothesis that IL-10 prevents NF-kappaB activation by stabilizing IkappaB-alpha.

Main Methods:

• Human monocytes were isolated and stimulated with LPS (100 ng/mL) with or without IL-10 (10 ng/mL).
• TNF-alpha levels in cell supernatants were quantified using ELISA.
• NF-kappaB activation was assessed by electrophoretic mobility shift assay, and IkappaB-alpha protein levels were determined by Western blot.

Main Results:

• LPS stimulation significantly increased TNF-alpha production in human monocytes.
• IL-10 treatment markedly reduced LPS-induced TNF-alpha release.
• LPS stimulation led to decreased IkappaB-alpha protein levels and increased NF-kappaB DNA binding, which were prevented by IL-10 pretreatment.

Conclusions:

• IL-10 inhibits LPS-induced TNF-alpha production in human monocytes.
• IL-10 preserves IkappaB-alpha protein levels, thereby preventing NF-kappaB activation.
• Stabilization of IkappaB-alpha by IL-10 is a key mechanism for reducing inflammatory cytokine release.